-
Mashup Score: 0
Expert tips from Whitney High, MD, at Elevate-Derm West 2024 guide experienced advanced practice providers in mastering dermatopathology and avoiding diagnostic pitfalls.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0
APPs found that patients on systemic therapies for AD experience fewer issues with adherence compared to those using topicals only.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
👥 A poster presented at the 2024 Elevate-Derm West Conference found the addition of systemic therapy to topical treatment in atopic dermatitis resulted in a higher proportion of patients being satisfied with their therapy. #dermtwitter https://t.co/a22IeIK4vW
-
-
Mashup Score: 0The Microbiome - 7 hour(s) ago
Dermatology and our patients have benefited greatly from scientific advances over the past decades.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, DermatologyTweet-
Advances in dermatology continue to revolutionize patient care, and the next big leap could be understanding the skin microbiome! https://t.co/KYB3DHV53N #Microbiome #Dermatology #FutureOfMedicine #PsoriasisTreatment #ChronicSkinDisease #BacteriophageTherapy
-
-
Mashup Score: 0Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome - 7 hour(s) ago
This case series examines treatment with anti–programmed cell death 1 (PD1) immunotherapy for patients with basal cell nevus syndrome.
Source: jamanetwork.comCategories: General Medicine News, DermatologyTweet-
Anti-PD1 therapy might present a viable systemic treatment option for patients with basal cell nevus syndrome refractory to hedgehog inhibitor, utilizing the immune system to combat new basal cell carcinoma occurrences. https://t.co/KkGvC32W5i @DrRobinReschke https://t.co/ZF3NipHI2L
-
-
Mashup Score: 0Pharmacokinetic Modeling of Spesolimab Reveals Key Differences Between IV and Subcutaneous Dosing for Generalized Pustular Psoriasis - 8 hour(s) ago
A poster presented at the 2024 Elevate-Derm West Conference outlines the pharmacokinetic profiles of spesolimab via intravenous and subcutaneous administration.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
👥 A poster presented at the 2024 Elevate-Derm West Conference highlighted pharmacokinetic data of spesolimab (Spevigo; Boehringer Ingelheim) via intravenous and subcutaneous routes. #dermtwitter https://t.co/1QO7LAup4t
-
-
Mashup Score: 2Day 1 Recap: Elevate-Derm West 2024 - 10 hour(s) ago
Catch up on coverage from the first day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
🌟 As we kick off another day of educational sessions, informative posters, and exclusive interviews at Elevate-Derm West in Scottsdale, check out our day 1 coverage to stay up-to-date on the latest and greatest. https://t.co/J15nTwYfw9
-
-
Mashup Score: 0Home - 16 hour(s) ago
Activity Overview
Source: na.eventscloud.comCategories: General Medicine News, DermatologyTweet-
🔍 Explore the latest in addressing unmet needs in uncontrolled HTN! Dive into MoAs of new treatment targets, current limitations, and novel strategies to reach BP goals. Build confidence in identifying patients for endothelin-targeted care.📍 https://t.co/v5z4SVTx5O #AHA24 https://t.co/CZ1bXUDkGi
-
-
Mashup Score: 1
Mark Gimbel, MD, and Whitney High, MD, presented complex cases that underscore the critical need for comprehensive approaches in diagnosing melanocytic lesions.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
🎥 EXPERT INSIGHTS: Mark Gimbel, MD, and Whitney High, MD, presented complex cases that underscore the critical need for comprehensive approaches in diagnosing melanocytic lesions. https://t.co/V2Q9InKx71
-
-
Mashup Score: 0
Bruce Strober, MD, PhD, introduces an upcoming series highlighting a clinical trial focused on the efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
How is spesolimab transforming GPP care? Learn from the Effisayil 2 trial’s key findings. Watch now: https://t.co/hIDCKTCVwZ https://t.co/hvNLITQ0Pk
-
-
Mashup Score: 3New Insights into Roflumilast Foam 0.3% for Scalp and Body Psoriasis: ARRECTOR Trial Patient Reported Outcomes - 1 day(s) ago
Roflumilast foam 0.3% significantly improved psoriasis severity, symptoms, and quality of life in patients with moderate to severe scalp and body psoriasis.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
📈 NEW DATA: Roflumilast (Zoryve; Arcutis) foam 0.3% significantly improved psoriasis severity, symptoms, and quality of life in patients with moderate to severe scalp and body psoriasis. #dermtwitter https://t.co/h6yHcIJZXf
-
👥 At the 2024 Elevate-Derm West Conference, Whitney High, MD, tailored a presentation to equip experienced advanced practice providers with insights and cautionary advice critical for dermatopathology practice. #dermtwitter https://t.co/VHqZElrN2t